Herman Waldmann
University of Oxford · 723 works · 49,209 citations · h-index 119
Top works
- Reshaping human antibodies for therapy
- Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo
- REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H
- Limiting Dilution Analysis of Cells in the Immune System
- Bone Marrow Transplantation for Patients with Chronic Myeloid Leukemia
- "Infectious" Transplantation Tolerance
- Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement
- Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.
- Humanised monoclonal antibody therapy for rheumatoid arthritis
- Functional analysis of T lymphocyte subsets in antiviral host defense.
- Monocytic origin of foam cells in human atherosclerotic plaques
- ELIMINATION OF GRAFT-VERSUS-HOST DISEASE BY IN-VITRO DEPLETION OF ALLOREACTIVE LYMPHOCYTES WITH A MONOCLONAL RAT ANTI-HUMAN LYMPHOCYTE ANTIBODY (CAMPATH-1)
- Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes
- Induction of classical transplantation tolerance in the adult.
- Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype
- CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells.
- Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
- In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation
- Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance
- Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse.